Beļģija - vācu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - lidocaine-hydrochlorid - injektionslösung - 20 mg/ml - lidocaine-hydrochlorid 100 mg - lidocaine

Beļģija - vācu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - ursodeoxycholic acid - hartkapsel - 250 mg - ursodeoxycholic acid 250 mg - ursodeoxycholic acid

Vācija - vācu - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

interchemie werken de adelaar eesti as (4401316) - calciumgluconat 1 h<2>o; magnesiumchlorid-hexahydrat; borsäure - infusionslösung - calciumgluconat 1 h<2>o (00060) 380 milligramm; magnesiumchlorid-hexahydrat (01042) 60 milligramm; borsäure (00050) 50 milligramm - schaf; rind; schwein

Eiropas Savienība - vācu - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Austrija - vācu - AGES (Agentur für Gesundheit und Ernährungssicherheit)

interchemie werken de adelaar eesti as - borsÄure; calciumgluconat monohydrat; magnesiumchlorid hexahydrat -

Eiropas Savienība - vācu - EMA (European Medicines Agency)

alfasigma s.p.a. - methylthioniniumchlorid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Austrija - vācu - AGES (Agentur für Gesundheit und Ernährungssicherheit)

kalceks as - apomorphinhydrochlorid hemihydrat -

Austrija - vācu - AGES (Agentur für Gesundheit und Ernährungssicherheit)

as grindeks - bupivacainhydrochlorid monohydrat -

Austrija - vācu - AGES (Agentur für Gesundheit und Ernährungssicherheit)

interchemie werken de adelaar eesti as - xylazin hydrochlorid -

Beļģija - vācu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - oxytocin - injektionslösung, infusionslösung - 5 iu/ml - oxytocin 5 iu/ml - oxytocin